Evidence map›Paper›PMID 37816332›Full record

ArticleCancer cell2023

Systematic investigation of mitochondrial transfer between cancer cells and T cells at single-cell resolution.

Hongyi Zhang, Xuexin Yu, Jianfeng Ye, Huiyu Li, Jing Hu, Yuhao Tan, Yan Fang, Esra Akbay, Fulong Yu, Chen Weng and 6 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Translational pediatrics · 2026
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Hongyi ZhangLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA; Center for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Xuexin YuLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA; Center for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Jianfeng YeLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Huiyu LiHamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Jing HuLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA; Center for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Yuhao TanLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Yan FangDepartment of Molecular Biology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Esra AkbayDepartment of Pathology, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Fulong YuBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Chen WengBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Vijay G SankaranBroad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Robert M BachooDepartment of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Elizabeth MaherDepartment of Neurology and Neurotherapeutics, UT Southwestern Medical Center, Dallas, TX 75390, USA.
John MinnaHamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, TX 75390, USA.
Anli ZhangLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: anli.zhang@utsouthwestern.edu.
Bo LiLyda Hill Department of Bioinformatics, UT Southwestern Medical Center, Dallas, TX 75390, USA; Center for Computational and Genomic Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: lib3@chop.edu.
Southwestern Medical Center · USChildren's Hospital of Philadelphia · USBroad Institute · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
Tracking Peripheral T-Cell Repertoire Changes for Preoperative and Early Ovarian Cancer DiagnosisR01CA258524 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Jayanthi S Lea, Bo Li · 2022 to 2026
$3.8M
Understanding the role of IDH in malignant gliomasR01CA154843 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI MAHER, ELIZABETH A · 2012 to 2022
$3.5M
Antigen-independent prediction and biomarker identification of cancer-specific T cellsR01CA245318 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI LI, BO · 2020 to 2024
$1.9M
NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA154843NCI NIH HHS R01 CA245318NCI NIH HHS R01 CA258524
6 · The paper itself

Abstract

Mitochondria (MT) participate in most metabolic activities of mammalian cells. A near-unidirectional mitochondrial transfer from T cells to cancer cells was recently observed to "metabolically empower" cancer cells while "depleting immune cells," providing new insights into tumor-T cell interaction and immune evasion. Here, we leverage single-cell RNA-seq technology and introduce MERCI, a statistical deconvolution method for tracing and quantifying mitochondrial trafficking between cancer and T cells. Through rigorous benchmarking and validation, MERCI accurately predicts the recipient cells and their relative mitochondrial compositions. Application of MERCI to human cancer samples identifies a reproducible MT transfer phenotype, with its signature genes involved in cytoskeleton remodeling, energy production, and TNF-α signaling pathways. Moreover, MT transfer is associated with increased cell cycle activity and poor clinical outcome across different cancer types. In summary, MERCI enables systematic investigation of an understudied aspect of tumor-T cell interactions that may lead to the development of therapeutic opportunities.

Indexed as

DNA, MitochondrialNeoplasmsAnimalsHumansMammalsMitochondriaT-LymphocytesDNA, MitochondrialMitochondrial TransfermtDNA sequencing.single cell genomicsStatistical DeconvolutionT cell dysfunctionTumor-Immune Interaction

Identifiers

PMID37816332
PMCPMC10568073
OpenAlexW4387444845

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.